Companies › Gemma Biotherapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PBGM01 AAVhu68 viral vector delivering functional GLB1 gene | GLB1 | Phase 1 | GM1 Gangliosidosis | Feb 2028 |
| GB221 Gene therapy delivering functional SMN1 gene via AAV vector to motor neurons | SMN1 | Phase 1 | Spinal Muscular Atrophy Type I | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04713475 | PBGM01 | Phase 1 | GM1 Gangliosidosis | Metabolic and endocrine | Feb 2028 |
| NCT07070999 | GB221 | Phase 1 | Spinal Muscular Atrophy Type I | Neurology | Dec 2028 |
Novartis GeneCradle Lanyue Biotech (Hangzhou) Biocad Lantu Biopharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.